This further strengthens a SMAD4 loss-of-function driven increased sensitivity towards MEK-inhibitors that may be of use as a predictive biomarker for clinically successful MEK-inhibitor therapy in CRC. The gene discussed is SMAD4; the disease is colorectal carcinoma.